Telix Pharmaceuticals to Acquire Germany’s ITM in $1.65 Billion Deal

Melbourne-based Telix Pharmaceuticals has agreed to acquire Germany’s ITM Isotope Technologies Munich for $1.65 billion upfront, in a deal announced on 21 September 2026 that the companies describe as a major consolidation move in the radiopharmaceutical industry.

Deal Structure

The agreement includes $1.25 billion in Telix shares to be issued to ITM’s sellers, about $302 million in ITM net debt to be assumed by Telix, and $96 million in management equity rollover, according to a regulatory filing. Telix could pay up to a further $700 million in contingent milestone payments tied to regulatory approvals and sales performance, including for ITM’s lead candidate, a lutetium-177-based radiopharmaceutical aimed at gastroenteropancreatic neuroendocrine tumours. Once the deal closes, expected by the end of 2026, Telix shareholders will own about 76.3% of the combined company, with ITM’s backers holding the remainder.

Building a Vertically Integrated Supplier

Telix said the acquisition would make it a vertically integrated radiopharmaceutical company by combining its own drug development work with ITM’s manufacturing infrastructure and distribution network, which the companies said spans more than 65 countries. Analysts at William Blair described the transaction as “supercritical,” saying it addressed one of the most complex challenges in operating a radiopharmaceutical business: securing reliable isotope production and supply. The deal follows a setback for ITM’s lead candidate, which the US Food and Drug Administration declined to approve in August 2026 over manufacturing concerns rather than clinical safety or efficacy issues, underscoring why reliable production capacity has become a priority for radiopharmaceutical developers. The combined group is projected to generate more than $1.3 billion in unaudited revenue this year.

Why It Matters

Radiopharmaceuticals, which use radioactive isotopes to diagnose and treat diseases including certain cancers, depend on complex, time-sensitive manufacturing and distribution chains that have historically limited the sector’s growth. By combining Telix’s clinical pipeline with ITM’s production capacity, the deal reflects a broader industry push to secure supply chains as demand for precision nuclear medicine grows, a dynamic likely to shape further consolidation among radiopharmaceutical developers.